| Expression pattern: |
DN |
| Associated gene: |
METTL3, p53, p21 |
| Associated microRNA: |
- |
| Biological function: |
hsa_circ_0131922 functions as a tumor suppressor in PTC; its overexpression suppresses PTC cell proliferation, migration, invasion, and xenograft tumor growth. |
| Molecular mechanism: |
METTL3-mediated m6A modification of hsa_circ_0131922 attenuates PTC progression by activating/regulating the p53/p21 pathway. |
| Biological pathway or process: |
p53 signaling (promotes); proliferation (inhibits); migration (inhibits); invasion (inhibits); m6A modification (other); other pathway/process (inhibits) |
| Detected method: |
Q
M
|
| Validation methods: |
RNase R Treatment; RT-qPCR; Microarray; MeRIP / MeRIP-seq; Transfection; CCK8; Wound Healing Assay; Transwell Assay; Western Blot; In Vivo Animal Model; Clinical Sample Validation; Survival Analysis; Bioinformatics Analysis |
| Clinical significance: |
Lower hsa_circ_0131922 levels correlated with poor prognosis in PTC patients; hsa_circ_0131922 could be a predictive prognostic biomarker and therapeutic target for PTC. |
| Description: |
hsa_circ_0131922 is a human circRNA derived from GCLC and is downregulated in PTC tissues and cell lines. It acts as a tumor suppressor: overexpression inhibits proliferation, migration, invasion, and xenograft tumor growth, while activating the p53/p21 pathway. METTL3 mediates m6A modification of hsa_circ_0131922, and low hsa_circ_0131922 expression is associated with poor prognosis in PTC patients. |
| Confidence score: |
0.7855 |